Sample size considerations for historical control studies with survival outcomes

ABSTRACT Historical control trials (HCTs) are frequently conducted to compare an experimental treatment with a control treatment from a previous study, when they are applicable and favored over a randomized clinical trial (RCT) due to feasibility, ethics and cost concerns. Makuch and Simon developed a sample size formula for historical control (HC) studies with binary outcomes, assuming that the observed response rate in the HC group is the true response rate. This method was extended by Dixon and Simon to specify sample size for HC studies comparing survival outcomes. For HC studies with binary and continuous outcomes, many researchers have shown that the popular Makuch and Simon method does not preserve the nominal power and type I error, and suggested alternative approaches. For HC studies with survival outcomes, we reveal through simulation that the conditional power and type I error over all the random realizations of the HC data have highly skewed distributions. Therefore, the sampling variability of the HC data needs to be appropriately accounted for in determining sample size. A flexible sample size formula that controls arbitrary percentiles, instead of means, of the conditional power and type I error, is derived. Although an explicit sample size formula with survival outcomes is not available, the computation is straightforward. Simulations demonstrate that the proposed method preserves the operational characteristics in a more realistic scenario where the true hazard rate of the HC group is unknown. A real data application of an advanced non-small cell lung cancer (NSCLC) clinical trial is presented to illustrate sample size considerations for HC studies in comparison of survival outcomes.

[1]  Song Zhang,et al.  Sample size calculation for studies comparing binary outcomes using historical controls , 2013, Biometrical journal. Biometrische Zeitschrift.

[2]  J J Lee,et al.  Uniform power method for sample size calculation in historical control studies with binary response. , 2001, Controlled clinical trials.

[3]  C. Pinsky Experience with historical control studies in cancer immunotherapy. , 1984, Statistics in medicine.

[4]  I. Yu,et al.  Mesothelioma and lung cancer mortality: a historical cohort study among asbestosis workers in Hong Kong. , 2012, Lung cancer.

[5]  D. Wackerly,et al.  SOME OBSERVATIONS ON THE MAKUCH/SIMON APPROACH TO SAMPLE SIZE DETERMINATION IN CLINICAL TRIALS WITH HISTORICAL CONTROLS , 2001 .

[6]  J. Ibrahim,et al.  Using Historical Controls to Adjust for Covariates in Trend Tests for Binary Data , 1998 .

[7]  Chul Ahn,et al.  Calculating sample size in trials using historical controls , 2010, Clinical trials.

[8]  Keith E Muller,et al.  Adjusting power for a baseline covariate in linear models , 2003, Statistics in medicine.

[9]  L J Emrich,et al.  Required duration and power determinations for historically controlled studies of survival times. , 1989, Statistics in medicine.

[10]  Hui Gao,et al.  Erlotinib in patients with advanced non-small-cell lung cancer: A meta-analysis. , 2012, Translational lung cancer research.

[11]  I. Loudon The use of historical controls and concurrent controls to assess the effects of sulphonamides, 1936–1945 , 2008, Journal of the Royal Society of Medicine.

[12]  J. Ware,et al.  Randomized clinical trials. Perspectives on some recent ideas. , 1976, The New England journal of medicine.

[13]  R W Makuch,et al.  Sample size considerations for non-randomized comparative studies. , 1980, Journal of chronic diseases.

[14]  Meinhard Kieser,et al.  On the Use of the Upper Confidence Limit for the Variance from a Pilot Sample for Sample Size Determination , 1996 .

[15]  Boris Freidlin,et al.  Conditional power calculations for clinical trials with historical controls , 2006, Statistics in medicine.

[16]  N. Keiding Historical controls and modern survival analysis , 1995, Lifetime data analysis.

[17]  S J Pocock,et al.  The combination of randomized and historical controls in clinical trials. , 1976, Journal of chronic diseases.

[18]  E. Gehan,et al.  The evaluation of therapies: historical control studies. , 1984, Statistics in Medicine.

[19]  R. Govindan,et al.  Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  A. Buchs,et al.  Incidence of malignancies in patients with diabetes mellitus and correlation with treatment modalities in a large Israeli health maintenance organization: a historical cohort study. , 2011, Metabolism: clinical and experimental.

[21]  R Simon,et al.  Sample size considerations for studies comparing survival curves using historical controls. , 1988, Journal of clinical epidemiology.

[22]  E. Gehan Randomized or historical control groups in cancer clinical trials: are historical controls valid? , 1986, Journal of Clinical Oncology.